肺癌脑转移的放射治疗
Radiotherapy for Brain Metastases from Lung Cancer
DOI: 10.12677/ACM.2023.1381770, PDF,   
作者: 李媛媛, 赵 红*：延安大学附属医院肿瘤科，陕西 延安
关键词: 肺癌；脑转移；放射治疗；Lung Cancer； Brain Metastasis； Radiation Therapy
摘要: 肺癌是脑转移瘤(brain metastases, BM)最常见的原发肿瘤，大约40%的肺癌患者将在整个病程中发展为脑转移，肺癌患者在诊断为脑转移后存活率显著下降。历史上，全脑放射治疗(WBRT)是脑转移瘤的标准治疗方法，最近，立体定向放射外科(SRS)已经成为1~4个转移性脑病变患者的标准方法。本文就小细胞肺癌(small cell lung cancer, SCLC)和非小细胞肺癌(non-small cell lung cancer, NSCLC)的脑转移的放射治疗进行综述。
Abstract: Lung cancer is the most common primary tumor for brain metastases (BM), and approximately 40% of lung cancer patients will develop brain metastases throughout the course of their disease, with a significant decrease in survival after diagnosis of brain metastases in lung cancer patients. Histori-cally, whole brain radiation therapy (WBRT) was the standard of care for brain metastases, and more recently, stereotactic radiosurgery (SRS) has become the standard of care for patients with 1~4 metastatic brain lesions. This article reviews the radiotherapy for brain metastases in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
文章引用：李媛媛, 赵红. 肺癌脑转移的放射治疗[J]. 临床医学进展, 2023, 13(8): 12623-12628. https://doi.org/10.12677/ACM.2023.1381770

参考文献

[1] Wolfson, A.H., Bae, K., Komaki, R., et al. (2011) Primary Analysis of a Phase II Randomized Trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of Different Total Doses and Schedules of Prophylactic Cranial Irradiation on Chronic Neurotoxicity and Quality of Life for Patients with Limited-Disease Small-Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 81, 77-84. [Google Scholar] [CrossRef] [PubMed]
[2] Cacho-Díaz, B., Spínola-Maroño, H., González-Aguilar, A., et al. (2018) Factors Associated with Long-Term Survival in Central Nervous System Metastases. Journal of Neuro-Oncology, 140, 159-164. [Google Scholar] [CrossRef] [PubMed]
[3] Arrieta, O., Maldonado, F., Turcott, J.G., et al. (2021) Prophylac-tic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized Phase 2 Study (PRoT-BM Trial). International Journal of Radiation Oncology, Biology, Physics, 110, 1442-1450. [Google Scholar] [CrossRef] [PubMed]
[4] Leskinen, S., Shah, H.A., Yaffe, B., et al. (2023) Hippocampal Avoidance in Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: A Systematic Review and Meta-Analysis. Journal of Neuro-Oncology, 163, 515-527. [Google Scholar] [CrossRef] [PubMed]
[5] Brown, P.D., Ahluwalia, M.S., Khan, O.H., et al. (2018) Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? Journal of Clinical Oncology, 36, 483-491. [Google Scholar] [CrossRef] 
[6] Lee, J. and Ahn, M.J. (2021) Brain Metastases in Patients with Oncogenic-Driven Non-Small Cell Lung Cancer: Pros and Cons for Early Radiotherapy. Cancer Treatment Reviews, 100, Article ID: 102291. [Google Scholar] [CrossRef] [PubMed]
[7] Brown, P.D., Gondi, V., Pugh, S., et al. (2020) Hippocampal Avoidance during Whole-Brain Radiotherapy plus Memantine for Patients with Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 38, 1019-1029. [Google Scholar] [CrossRef] 
[8] Faramand, A., Niranjan, A., Kano, H., et al. (2019) Primary or Salvage Stereotactic Radiosurgery for Brain Metastatic Small Cell Lung Cancer. Journal of Neuro-Oncology, 144, 217-225. [Google Scholar] [CrossRef] [PubMed]
[9] Weiner, J.P. (2020) Neurocognitive Outcomes for Patients with Brain Metastasis in the Modern Era: Benefit of Treatment with Hippocampal Avoidance Whole-Brain Radiotherapy plus Memantine. Journal of Clinical Oncology, 38, 1003-1005. [Google Scholar] [CrossRef] 
[10] Bernhardt, D., Adeberg, S., Bozorgmehr, F., et al. (2018) Outcome and Prognostic Factors in Single Brain Metastases from Small-Cell Lung Cancer. Strahlentherapie und Onkologie, 194, 98-106. [Google Scholar] [CrossRef] [PubMed]
[11] Ni, M., Jiang, A., Liu, W., et al. (2020) Whole Brain Radiation Therapy plus Focal Boost May Be a Suitable Strategy for Brain Metastases in SCLC Patients: A Multi-Center Study. Ra-diation Oncology, 15, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, H., Xu, L., Wang, Y., et al. (2018) Additional Radiation Boost to Whole Brain Radiation Therapy May Improve the Survival of Patients with Brain Metastases in Small Cell Lung Cancer. Radiation Oncology, 13, Article No. 250. [Google Scholar] [CrossRef] [PubMed]
[13] Gui, C., Chintalapati, N., Hales, R.K., et al. (2019) A Prospective Evaluation of Whole Brain Volume Loss and Neurocognitive Decline Following Hippocampal-Sparing Prophylactic Cra-nial Irradiation for Limited-Stage Small-Cell Lung Cancer. Journal of Neuro-Oncology, 144, 351-358. [Google Scholar] [CrossRef] [PubMed]
[14] Kuntz, L., Le Fèvre, C., Jarnet, D., et al. (2023) Acute Toxicities and Cumulative Dose to the Brain of Repeated Sessions of Stereotactic Radiotherapy (SRT) for Brain Metastases: A Retrospective Study of 184 Patients. Radiation Oncology, 18, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[15] Rusthoven, C.G., Yamamoto, M., Bernhardt, D., et al. (2020) Evaluation of First-Line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncology, 6, 1028-1037. [Google Scholar] [CrossRef] [PubMed]
[16] Yamamoto, M., Serizawa, T., Higuchi, Y., et al. (2017) A Mul-ti-Institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients with Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-Related Complications and Long-Term Maintenance of Mini-Mental State Exam-ination Scores. International Journal of Radiation Oncology, Biology, Physics, 99, 31-40. [Google Scholar] [CrossRef] [PubMed]
[17] Miccio, J.A., Barsky, A., Gao, S., et al. (2020) Multi-Institutional Retrospective Review of Stereotactic Radiosurgery for Brain Metastasis in Patients with Small Cell Lung Cancer without Prior Brain-Directed Radiotherapy. Journal of Radiosurgery & SBRT, 7, 19-27.
[18] Fan, X., Yang, L., Qin, W., et al. (2023) Prophylactic Cranial Irradiation-Related Lymphopenia Affects Survival in Patients with Limited-Stage Small Cell Lung Cancer. Heliyon, 9, e16483. [Google Scholar] [CrossRef] [PubMed]
[19] Crockett, C., Belderbos, J., Levy, A., et al. (2021) Prophylactic Cranial Irradiation (PCI), Hippocampal Avoidance (HA) Whole Brain Radiotherapy (WBRT) and Stereotactic Radiosurgery (SRS) in Small Cell Lung Cancer (SCLC): Where Do We Stand? Lung Cancer, 162, 96-105. [Google Scholar] [CrossRef] [PubMed]
[20] Rodríguez de Dios, N., Couñago, F., Mur-cia-Mejía, M., et al. (2021) Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study. Journal of Clinical Oncology, 39, 3118-3127. [Google Scholar] [CrossRef] 
[21] De Ruiter, M.B., Groot, P.F.C., Deprez, S., et al. (2023) Hippocampal Avoidance Prophylactic Cranial Irradiation (HA-PCI) for Small Cell Lung Cancer Reduces Hippocampal Atrophy Compared to Conventional PCI. Neuro-Oncology, 25, 167-176. [Google Scholar] [CrossRef] [PubMed]
[22] Vees, H., Caparrotti, F., Eboulet, E.I., et al. (2020) Impact of Early Prophylactic Cranial Irradiation with Hippocampal Avoidance on Neurocognitive Function in Patients with Limited Dis-ease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12). International Journal of Radiation Oncology, Biology, Physics, 107, 279-287. [Google Scholar] [CrossRef] [PubMed]
[23] Belderbos, J.S.A., De Ruysscher, D.K.M., De Jaeger, K., et al. (2021) Phase 3 Randomized Trial of Prophylactic Cranial Irradiation with or without Hippocampus Avoidance in SCLC (NCT01780675). Journal of Thoracic Oncology, 16, 840-849. [Google Scholar] [CrossRef] [PubMed]
[24] Takahashi, T., Yamanaka, T., Seto, T., et al. (2017) Prophylactic Cranial Irradiation versus Observation in Patients with Extensive-Disease Small-Cell Lung Cancer: A Multicentre, Ran-domised, Open-Label, Phase 3 Trial. The Lancet Oncology, 18, 663-671. [Google Scholar] [CrossRef] 
[25] Witlox, W.J.A., Ramaekers, B.L.T., Lacas, B., et al. (2021) Individual Patient Data Meta-Analysis of Prophylactic Cranial Irradiation in Locally Advanced Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 158, 40-47. [Google Scholar] [CrossRef] [PubMed]
[26] Witlox, W.J.A., Ramaekers, B.L.T., Lacas, B., et al. (2022) Cost-Effectiveness of Prophylactic Cranial Irradiation in Stage III Non-Small Cell Lung Cancer. Radiotherapy and On-cology, 170, 95-101. [Google Scholar] [CrossRef] [PubMed]
[27] Sun, A., Hu, C., Wong, S.J., et al. (2019) Prophylactic Cranial Irradiation vs Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Long-Term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial. JAMA Oncology, 5, 847-855. [Google Scholar] [CrossRef] [PubMed]
[28] Li, M., Wang, T., Wen, P., et al. (2021) Treatment and Toxic Effects of Prophylactic Cranial Irradiation in Stage II-III Non-Small Cell Lung Cancer: A Meta-Analysis. Asia-Pacific Journal of Clinical Oncology, 17, e18-e26. [Google Scholar] [CrossRef] [PubMed]
[29] Gore, E.M., Bae, K., Wong, S.J., et al. (2011) Phase III Comparison of Prophylactic Cranial Irradiation versus Observation in Patients with Locally Advanced Non-Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214. Journal of Clinical Oncology, 29, 272-278. [Google Scholar] [CrossRef] 
[30] De Ruysscher, D., Dingemans, A.C., Praag, J., et al. (2018) Prophylactic Cranial Irradiation versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Ran-domized Phase III NVALT-11/DLCRG-02 Study. Journal of Clinical Oncology, 36, 2366-2377. [Google Scholar] [CrossRef] 
[31] Witlox, W.J.A., Ramaekers, B.L.T., Joore, M.A., et al. (2020) Health-Related Quality of Life after Prophylactic Cranial Irradiation for Stage III Non-Small Cell Lung Cancer Patients: Results from the NVALT-11/DLCRG-02 Phase III Study. Radiotherapy and Oncology, 144, 65-71. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, X.S., Bai, Y.F., Verma, V., et al. (2023) Randomized Trial of First-Line Tyrosine Kinase Inhibitor with or without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 115, 742-748. [Google Scholar] [CrossRef] [PubMed]
[33] Ma, J., Pi, G., Bi, J., et al. (2021) Concurrent Apatinib and Brain Radio-therapy in Patients with Brain Metastases from Driver Mutation-Negative Non-Small-Cell Lung Cancer: Study Protocol for an Open-Label Randomized Controlled Trial. Clinical Lung Cancer, 22, e211-e214. [Google Scholar] [CrossRef] [PubMed]
[34] Chen, L., Tong, F., Peng, L., et al. (2022) Efficacy and Safety of Recombinant Human Endostatin Combined with Whole-Brain Radiation Therapy in Patients with Brain Metastases from Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 174, 44-51. [Google Scholar] [CrossRef] [PubMed]
[35] Mulvenna, P., Nankivell, M., Barton, R., et al. (2016) Dexame-thasone and Supportive Care with or without Whole Brain Radiotherapy in Treating Patients with Non-Small Cell Lung Cancer with Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy (QUARTZ): Results from a Phase 3, Non-Inferiority, Randomised Trial. The Lancet, 388, 2004-2014. [Google Scholar] [CrossRef] 
[36] Pechoux, C.L., Dhermain, F. and Besse, B. (2016) Whole Brain Radiotherapy in Patients with NSCLC and Brain Metastases. The Lancet, 388, 1960-1962. [Google Scholar] [CrossRef] 

为你推荐